Ultragenyx Pharmaceutical | RARE - Sales Revenues


Ultragenyx Pharmaceutical reported $214M in Sales Revenues for its fiscal quarter ending in June of 2026.





Sales Change Date
Acadia Pharmaceuticals USD 307.96M 39.9M Jun/2026
Agios Pharmaceuticals USD 44.74M 25.94M Jun/2026
Alnylam Pharmaceuticals USD 1.29B 120M Jun/2026
BioCryst Pharmaceuticals USD 218.25M 188.3M Jun/2026
BioMarin Pharmaceutical USD 990M 224M Jun/2026
Insmed USD 425.49M 119.53M Jun/2026
Ionis Pharmaceuticals USD 268M 22M Jun/2026
Karyopharm Therapeutics USD 35.07M 987K Mar/2026
Kyowa Hakko Kirin JPY 145.16B 26.69B Jun/2026
MacroGenics USD 20.8M 20.43M Mar/2026
Moderna USD 100M 289M Jun/2026
Neurocrine Biosciences USD 959M 148M Jun/2026
PTC Therapeutics USD 361M 88M Jun/2026
Puma Biotechnology USD 80.54M 33.46M Sep/2024
Regeneron Pharmaceuticals USD 4.29B 690M Jun/2026
Sarepta Therapeutics USD 401.3M 329.5M Jun/2026
Ultragenyx Pharmaceutical USD 214M 78M Jun/2026
Vertex Pharmaceuticals USD 3.33B 340M Jun/2026